ABSTRACT Cold atmospheric plasma (CAP) with ViroCAP‐plasma represents a promising therapeutic innovation in dermatology, offering clinicians a nonpharmacologic option for managing inflammatory skin conditions like intertriginous dermatitis, especially when conventional treatments are contraindicated, ineffective, or poorly tolerated.
Vinas et al. (2026) studied this question.